White House claims Trump’s drug pricing deals may save $529 billion
White House economists project that President Trump’s agreements with drug companies to align US prescription prices with those in other countries could save $529 billion over the next decade. Analysis reveals the first economy-wide projections tied to a key policy in Trump’s pitch to voters ahead of November’s midterm elections for House and Senate control. Democratic lawmakers doubt Trump’s claimed savings, and these new figures will likely raise more questions about the data. Voters are increasingly worried about cost-of-living issues, with rising energy prices from the Iran war amplifying public anxiety. Trump aims to tackle affordability by negotiating with companies to lower prescription drug costs in the US, aligning them with prices in other wealthy nations. “You now have the lowest drug prices anywhere in the world,” Trump declared at a Florida rally for seniors on Friday. “That alone should secure the midterms.”
White House economic advisers conducted the analysis. Federal and state governments could save $64.3 billion on Medicaid over the next decade thanks to Trump’s “most favoured nation” drug pricing policy. Details of the Trump administration’s deals with 17 top pharmaceutical companies remain scarce, complicating efforts to verify the claimed savings. The White House analysis estimated potential savings as new medications enter the market under Trump’s framework, with one model projecting $733 billion in savings over ten years. Trump and his Health and Human Services team have hailed his drug-pricing deals as revolutionary, pushing Congress to make them law. Democrats dispute the administration’s savings claims.
Senate Finance Committee’s Ron Wyden and 17 Democrats proposed a measure in April mandating the administration to reveal pharmaceutical companies’ agreement terms. Why is the Trump administration hiding these great deals from the public? Wyden announced the measure. Health Secretary Robert F. Kennedy Jr. announced his team will disclose details excluding proprietary information or trade secrets. Trump administration’s estimated savings could be significant, with Americans spending $467 billion on prescription drugs in 2024, based on the latest government data. The analysis suggests that foreign countries would pay more for prescription drugs, diversifying drugmakers’ revenue sources and supporting innovation in new treatments. In October 2024, the Congressional Budget Office estimated that a plan akin to Trump’s could cut prescription drug prices by over 5 percent, though this reduction “would likely decrease over time as manufacturers adapted by changing prices or distribution in other countries.”
Trump’s claimed savings will likely draw more scrutiny from Democrats, who argue that any price cuts could be negated by rising costs for prescription drugs outside the “most favoured nation” framework. Pharma profits soar alongside administration ties. In April, staff for Sen. Bernie Sanders, I-Vt., released an analysis showing that 15 companies involved in the drug-pricing plan saw their combined profits soar 66 percent over the past year, reaching $177 billion. The report highlighted that last year’s tax cuts signed by Trump “exempted or delayed numerous costly drugs” from Medicare price negotiations. The Trump administration argues that Sanders’ critique is flawed, claiming it relies on list prices for drugs rather than the actual prices patients pay.
